RxDoctor Payments Data

Alvin Tenchavez, MD

Internal Medicine · Boaz, ALNPI 1225023211

Payments from drug & device makers

$9,633in general payments, 2019–2025

Across 626 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AstraZeneca$775
  • Otsuka America Pharmaceutical, Inc.$702
  • Amgen$610
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$9,50299%
  • Education$1321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)115$1,203
GSK77$1,097
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC65$1,012
AstraZeneca35$775
Otsuka America Pharmaceutical, Inc.28$702
Amgen41$610
Lilly USA, LLC21$302
Bayer22$297
Johnson & Johnson13$263
Pfizer14$260
Merck16$251
Novartis9$189
Supernus Pharmaceuticals, Inc.21$163
Lundbeck LLC9$154
Amarin Pharma, Inc.9$154
Novo Nordisk10$144
Harmony Biosciences LLC3$135
Sanofi-aventis U.S. LLC7$119
Vanda Pharmaceuticals Inc.5$119
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$109
Takeda Pharmaceuticals U.S.A., Inc.5$101
Eisai Inc.7$94
Jazz Pharmaceuticals Inc.4$85
Exact Sciences6$82
Astellas Pharma US Inc5$75
Sumitomo Pharma America, Inc.6$60
Ironwood Pharmaceuticals, Inc3$57
Sunovion Pharmaceuticals Inc.7$57
Ardelyx, Inc.3$55
Genentech USA, Inc.3$50
Acadia Pharmaceuticals Inc3$49
Daiichi Sankyo Inc.3$48
Melinta Therapeutics, LLC3$45
Biohaven Pharmaceutical Holding Company Ltd.2$45
Boehringer Ingelheim3$44
Xeris Pharmaceuticals, Inc.2$44
Sanofi Pasteur Inc.3$37
E.r. Squibb & Sons, L.L.C.3$37
Esperion Therapeutics, Inc.2$35
Redhill Biopharma Inc.2$35
Inspire Medical Systems, Inc.1$34
Axsome Therapeutics, Inc.2$30
Biohaven Pharmaceuticals, Inc.2$29
Averitas Pharma Inc.1$29
Medtronic2$27
Teva Pharmaceuticals USA, Inc.2$27
Bioventus LLC1$25
Dexcom, Inc.1$24
Zyla Life Sciences, Inc.1$20
Antares Pharma, Inc.1$20
Mylan Specialty L.p.1$20
Neurocrine Biosciences, Inc.1$19
Phathom Pharmaceuticals, Inc.1$18
Sun Pharmaceutical Industries Inc.1$18
Idorsia Pharmaceuticals US Inc1$17
Boston Scientific1$16
Avanir Pharmaceuticals, Inc.1$16
SK Life Science, Inc.1$16
Vertex1$14
Corium, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,633 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$71,222
Medicare patients
223
Services billed
1,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$108,150
EliquisApixaban116$58,640
FarxigaDapagliflozin Propanediol59$40,600
TrulicityDulaglutide41$38,205
JanuviaSitagliptin Phosphate46$35,171
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$32,443
JardianceEmpagliflozin36$29,956
Repatha SureclickEvolocumab40$29,820
MounjaroTirzepatide28$29,205
LinzessLinaclotide34$22,497
Xtampza ErOxycodone Myristate11$19,120
TradjentaLinagliptin18$16,254
Janumet XrSitagliptin Phos/Metformin Hcl19$12,084
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen594$10,873
Xigduo XrDapaglifloz Propaned/Metformin16$9,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$144$108,15094 claims
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$302$70,22581 claims
PfizerEliquis$260$58,640116 claims
MerckJanuvia, Janumet Xr$251$47,25565 claims
Boehringer IngelheimJardiance, Tradjenta$44$46,21054 claims
AstraZenecaFarxiga$775$40,60059 claims
GSKTrelegy Ellipta, Breo Ellipta$1,097$37,37455 claims
AbbVieLinzess, Restasis$1,203$29,23645 claims
Astellas Pharma US IncMyrbetriq$75$8,14614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Boaz

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →